Dopo l'orario di chiusura: 5.06 0.03 +0.60%

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc Borsa (ELTX) Ultime notizie

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc Borsa (ELTX) Ultime notizie

Elicio Therapeutics reports inducement grants - TipRanks

Elicio Therapeutics Reports Inducement Grants - GlobeNewswire

Elicio Therapeutics Reports Inducement Grants - EIN News

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian

Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan

Elicio Therapeutics CFO resigns to pursue new opportunity By Investing.com - Investing.com Australia

Elicio Therapeutics CFO resigns to pursue new opportunity - Investing.com

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 - InvestorPlace

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - StockTitan

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - wallstreet:online

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - Yahoo Finance

Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering - Global Legal Chronicle

Therapeutic Vaccine Industry to Witness Massive Growth - openPR

ASCO 2024Chris Haqq - pharmaphorum

Ratios in Focus: Analyzing Elicio Therapeutics Inc. (ELTX)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - MSN

Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com Australia

Orion Group Holdings inks $30.5M land sale deal By Investing.com - Investing.com

Apple shares target raised, reiterates Outperform on AI potential By Investing.com - Investing.com

Elicio Therapeutics Shares Drop 35% After Public Offering Prices - MarketWatch

Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com UK

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?Elicio Therapeutics (NASDAQ ... - Benzinga

Elicio Therapeutics Prices of $11.5 Million Underwritten Public Offering - citybiz

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - GlobeNewswire

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - StockTitan

Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? - InvestorPlace

Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com Australia

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - Benzinga

Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com Australia

Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com

Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com India

Elicio Therapeutics launches public offering of stock and warrants - Investing.com

Elicio Therapeutics Shares Slip 28% After Public Offering, Drug Data - MarketWatch

Form 424B5 Elicio Therapeutics, - StreetInsider.com

SEC Form 424B5 filed by Elicio Therapeutics Inc. - Quantisnow

Elicio Therapeutics’ Promising Early Results in Cancer Vaccine Trial - TipRanks

Elicio Therapeutics Announces Proposed Public Offering - ForexTV.com

Elicio Therapeutics shares are trading lower after the company announced preliminary disease-free survival analysis ... - Quantisnow

Elicio Therapeutics Announces Proposed Public Offering - GlobeNewswire

Elicio Therapeutics Announces Proposed Public Offering - GlobeNewswire Inc.

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing ... - The Bakersfield Californian

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a ... - GlobeNewswire

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a ... - Yahoo Finance

Elicio Therapeutics Announces Proposed Public Offering - Yahoo Finance

Elicio Therapeutics Reports Inducement Grants - Yahoo Finance

Elicio Therapeutics Reports Inducement Grants - StockTitan

Long Term Trading Analysis for (ELTX) - Stock Traders Daily

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors - Nasdaq

(ELTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in ... - GlobeNewswire

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in ... - Yahoo Finance

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - Yahoo Finance

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 - InvestorPlace

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates - Yahoo Finance

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - Yahoo Finance

Broader KRAS inhibition methods include chaperoning, gluing, vaccinating - BioWorld Online

Retail investors who hold 45% of Elicio Therapeutics, Inc. (NASDAQ:ELTX) gained 14%, insiders profited as well - Simply Wall St

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination IndustryElicio Therapeu - Benzinga

Workday Inc. insider sells over $32.5 million in company stock By Investing.com - Investing.com

Simile a ELTX